The Full Wiki

More info on Astellas Pharma

Astellas Pharma: Map


Wikipedia article:

Map showing all locations mentioned on Wikipedia article:

 is a Japanesemarker pharmaceutical company, formed on 1 April, 2005 from the merger of   and  .

Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

The company's headquarters are in Tokyomarker, with research centres in Tsukuba and Osaka. Clinical development is centred in Deerfield, Illinoismarker and Leiderdorpmarker, Netherlandsmarker. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people.


Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943.

Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyomarker in 1942.

Both companies started their overseas expansion at about the same time, opening offices in Taiwanmarker in 1962 and 1963, respectively, and in the United Statesmarker and Europe from 1977 onwards. Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D centre in Deerfield, Illinoismarker. Yamanouchi's R&D centre in Leiderdorpmarker was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991.

Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April, 2005.


Some of the key products produced by Astellas include:


External links

Embed code:

Got something to say? Make a comment.
Your name
Your email address